Protara Therapeutics (NASDAQ:TARA) Issues Quarterly Earnings Results

Protara Therapeutics (NASDAQ:TARA) posted its earnings results on Wednesday. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09, Zacks reports.

Protara Therapeutics Stock Performance

TARA opened at $4.07 on Thursday. The company’s 50 day simple moving average is $4.49 and its 200 day simple moving average is $3.45. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48. The stock has a market capitalization of $83.96 million, a PE ratio of -1.44 and a beta of 1.69.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, March 6th. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.